Novocure Ltd. (038)
XMUN 
Summary
038 Chart
NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript
NovoCure Limited ( NVCR ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Ingrid Goldberg - VP of Investor Relations William Doyle - Executive Chairman Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - President Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Kevin Joaquin - Evercore ISI Institutional Equities, Research Division Tanmay Patwardhan Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum
Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technology offers a differentiated, device-based approach to cancer treatment, with recent milestones in glioblastoma, lung, and pancreatic cancers. Upcoming Q3 results and regulatory updates, including METIS and PANOVA-3, are key catalysts, supported by strong liquidity and cautious financial management.
Novocure Ltd. (038) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Novocure Ltd. ever had a stock split?
Novocure Ltd. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Ashley Cordova CEO | XMUN Exchange | JE00BYSS4X48 ISIN |
| JE Country | 1,488 Employees | - Last Dividend | - Last Split | 2 Oct 2015 IPO Date |
Overview
NovoCure Limited is a pioneering oncology company that specializes in the development, manufacture, and commercialization of its innovative tumor treating fields (TTFields) devices for the treatment of various solid tumor cancers. Founded in 2000, NovoCure maintains a strong international presence with operations in the United States, Germany, Japan, Greater China, and other global markets. The company is headquartered in Saint Helier, Jersey, highlighting its global reach and commitment to advancing cancer treatment worldwide. NovoCure's groundbreaking approach focuses on utilizing TTFields technology to target cancer cells, offering a novel treatment option beyond traditional methods. With ongoing clinical trials aimed at expanding the applications of TTFields, NovoCure continues to explore the potential of its technology in treating a wide range of cancers, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Products and Services
- Optune Gio:
- Optune Lua:
Optune Gio is one of NovoCure's flagship TTFields devices, designed specifically for the treatment of glioblastoma, a highly aggressive form of brain cancer. This device represents a significant advancement in the field of oncology, offering a non-invasive treatment option that utilizes low-intensity electric fields to disrupt cancer cell division and growth. By targeting glioblastoma cells while sparing healthy tissue, Optune Gio offers a promising treatment alternative for patients with this challenging condition.
Optune Lua is another innovative TTFields device offered by NovoCure, tailored for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure that affects the lining of the lungs. Like Optune Gio, Optune Lua employs TTFields technology to selectively target cancer cells, aiming to inhibit their proliferation and induce cell death. This device provides a critical option for mesothelioma patients, for whom treatment options are often limited and prognosis is typically poor.
Contact Information
